DDInter894 DDInter1376
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Hydroxyurea {u} (Compound) resembles {v} (Compound) Acetohydroxamic acid
Hydroxyurea {u} (Compound) treats {v} (Disease) hematologic cancer
Hydroxyurea {u} (Compound) binds {v} (Gene) CYP2D6
Hydroxyurea {u} (Compound) is included by {v} (Pharmacologic Class) Urea
Hydroxyurea {u} (Compound) causes {v} (Side Effect) Infestation NOS
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentostatin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Hydroxyurea {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Hydroxyurea (Compound) resembles Acetohydroxamic acid (Compound)
Hydroxyurea (Compound) treats hematologic cancer (Disease)
Hydroxyurea (Compound) binds CYP2D6 (Gene)
Hydroxyurea (Compound) is included by Urea (Pharmacologic Class)
Hydroxyurea (Compound) causes Infestation NOS (Side Effect)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Hydroxyurea may lead to a major life threatening interaction when taken with Leflunomide